BRPI0508440A - composições e métodos para diagnóstico tópico e transporte terapêutico - Google Patents

composições e métodos para diagnóstico tópico e transporte terapêutico

Info

Publication number
BRPI0508440A
BRPI0508440A BRPI0508440-7A BRPI0508440A BRPI0508440A BR PI0508440 A BRPI0508440 A BR PI0508440A BR PI0508440 A BRPI0508440 A BR PI0508440A BR PI0508440 A BRPI0508440 A BR PI0508440A
Authority
BR
Brazil
Prior art keywords
compositions
methods
topical
release
useful
Prior art date
Application number
BRPI0508440-7A
Other languages
English (en)
Inventor
Michael D Dake
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of BRPI0508440A publication Critical patent/BRPI0508440A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES E MéTODOS PARA DIAGNOSTICO TóPICO E TRANSPORTE TERAPêUTICO. A presente invenção refere-se a composições e métodos que são úteis para liberação, incluindo liberação transdérmica, de agentes biologicamente ativos, tais como, produtos terapêuticos de não nucleotideo e não proteina e produtos terapêuticos com base em proteina excluindo insulina, toxinas de botulina, fragmentos de anticorpo, e VEGF. As composições e métodos são particularmente úteis para liberação tópica de agentes antifúngicos e agentes antigênicos adequados para imunização. Alternativamente, as composições podem ser preparadas com componentes úteis para alvejar liberação das composições, bem como os componetes de imageamento.
BRPI0508440-7A 2004-03-03 2005-03-03 composições e métodos para diagnóstico tópico e transporte terapêutico BRPI0508440A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55001404P 2004-03-03 2004-03-03
PCT/US2005/006931 WO2005120546A2 (en) 2004-03-03 2005-03-03 Compositions and methods for topical diagnostic and therapeutic transport

Publications (1)

Publication Number Publication Date
BRPI0508440A true BRPI0508440A (pt) 2007-07-24

Family

ID=35503656

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508440-7A BRPI0508440A (pt) 2004-03-03 2005-03-03 composições e métodos para diagnóstico tópico e transporte terapêutico

Country Status (15)

Country Link
US (5) US8974774B2 (pt)
EP (1) EP1734984A4 (pt)
JP (2) JP2007527431A (pt)
KR (1) KR101284710B1 (pt)
CN (1) CN101083907B (pt)
AU (1) AU2005251676B2 (pt)
BR (1) BRPI0508440A (pt)
CA (2) CA2558676C (pt)
CR (1) CR20110355A (pt)
IL (1) IL177815A (pt)
MX (1) MXPA06009897A (pt)
NO (1) NO20064414L (pt)
NZ (1) NZ593986A (pt)
SG (1) SG150570A1 (pt)
WO (1) WO2005120546A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301213B1 (en) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
JP5305371B2 (ja) * 2007-07-19 2013-10-02 国立大学法人 岡山大学 生物膜透過性組成物及び薬剤の生物膜透過性増強方法
CN101842107B (zh) 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
CA2698103A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
BRPI0918988A2 (pt) * 2008-09-24 2015-12-01 Stabilitech Ltd métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
AU2009332947C1 (en) * 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
BR112012025047A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
EP2552410B1 (en) 2010-03-31 2018-10-24 Stabilitech Biopharma Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
HUE026885T2 (en) 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
AU2013234988A1 (en) * 2012-03-22 2014-10-09 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
US20190185837A1 (en) 2017-12-20 2019-06-20 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
EP3753568A1 (en) 2019-06-21 2020-12-23 Fastox Pharma SA Composition modulating botulinum neurotoxin effect
CN112679583B (zh) * 2021-01-07 2022-02-22 杭州医学院 一种靶向癌蛋白boris的特异性多肽及其应用和基因
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN114020363B (zh) * 2021-11-15 2023-12-15 海能达通信股份有限公司 群组附着方法及相应设备

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPS63287730A (ja) 1987-05-20 1988-11-24 Nippon Shokubai Kagaku Kogyo Co Ltd 経皮吸収促進剤およびこれを含有してなる皮膚外用剤
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
EP0554284B1 (en) 1990-10-24 1996-12-18 Allelix Biopharmaceuticals Inc. Peptide-based inhibitors of hiv replication
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
US5260082A (en) 1992-09-16 1993-11-09 Kraft General Foods, Inc. Baked goods, doughs or batters, dry mixes and methods for producing thereof
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ES2332905T3 (es) 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) * 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2755976B1 (fr) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6228161B1 (en) * 1996-12-30 2001-05-08 Minerals Technologies Inc. Use of calcium carbonate in an acidic aqueous media
US5798587A (en) * 1997-01-22 1998-08-25 Industrial Technology Research Institute Cooling loop structure of high speed spindle
FR2759298B1 (fr) * 1997-02-10 1999-04-09 Rhone Poulenc Rorer Sa Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
EP1030927A1 (en) 1997-11-12 2000-08-30 Valentis Inc. Expression plasmids for multiepitope nucleic acid-based vaccines
US5985434A (en) 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6011646A (en) 1998-02-20 2000-01-04 The Regents Of The Unviersity Of California Method to adjust multilayer film stress induced deformation of optics
DE69936355T2 (de) 1998-02-25 2008-02-21 The Government Of The United States, As Represented By The Secretary Of The Army Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der transkutanen Immunantwort
AU749475B2 (en) 1998-04-27 2002-06-27 Astellas Pharma Inc. Medicinal compositions
US6261679B1 (en) 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
TR200100254T2 (tr) * 1998-07-13 2001-06-21 Expression Genetics, Inc. Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.
US6280937B1 (en) * 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
EP1128844B1 (en) 1998-10-27 2006-01-04 Mayo Foundation For Medical Education And Research Botulinum toxins for enhancing wound healing
WO2000032764A1 (en) 1998-12-02 2000-06-08 I.D.M. Immuno-Designed Molecules New oligomeric conjugates liable to transfer biological molecules into cells
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
US6627632B2 (en) 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US7442764B2 (en) * 1999-06-07 2008-10-28 Mirns Bio Corporation Reversible modification of amine-containing compounds
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030236214A1 (en) 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
CA2381425A1 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6773928B1 (en) 1999-09-22 2004-08-10 The United States Of America As Represented By The Secretary Of The Army Compositions and methods for enhancing bioassay performance
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT411041B (de) * 2000-05-18 2003-09-25 Josef Lindenberg Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
EP1301213B1 (en) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
MXPA03007358A (es) 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
US7226605B2 (en) * 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
AU2002359679B2 (en) * 2001-12-11 2009-01-08 Cellgate, Inc. Guanidinium transport reagents and conjugates
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
AU2002360712A1 (en) * 2001-12-21 2003-07-30 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US20030147958A1 (en) * 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
US20050163832A1 (en) * 2002-02-13 2005-07-28 Vladimir Torchilin Intracellular delivery of therapeutic agents
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
EP1572941A4 (en) * 2002-02-26 2009-03-18 Maxygen Inc NEW FLAVIVIRUS ANTIGENES
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US7883720B2 (en) * 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) * 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
JP2006067889A (ja) * 2004-09-01 2006-03-16 Japan Science & Technology Agency Ｐｅｏと二本鎖核酸のコンジュゲート
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1869451B1 (en) * 2005-03-08 2013-06-26 Life Technologies Corporation Monitoring and manipulating cellular transmembrane potentials using nanostructures
CA2607595C (en) * 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
NZ598159A (en) 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
JP2010514781A (ja) 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
HRP20181259T1 (hr) * 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
CN102292126B (zh) * 2008-12-31 2016-10-12 雷文斯治疗公司 用于治疗色素沉着过度的组合物和方法
AU2009332947C1 (en) * 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
KR101959234B1 (ko) * 2009-04-01 2019-03-18 레반스 테라퓨틱스, 아이엔씨. 혈관 과민반응과 관련된 피부질환을 치료하기 위한 방법 및 조성물
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8586020B2 (en) 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
US20130071444A1 (en) * 2011-09-16 2013-03-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Amphiphilic Cationic Polymers and Methods of Use Thereof
CN104114572A (zh) * 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9541558B2 (en) * 2012-09-05 2017-01-10 California Institute Of Technology Cysteine hydrazide nicotinamide for glycomics and glycoproteomics uses
CA2889833A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis

Also Published As

Publication number Publication date
CN101083907B (zh) 2012-10-10
US20050239705A1 (en) 2005-10-27
CN101083907A (zh) 2007-12-05
US8092788B2 (en) 2012-01-10
EP1734984A2 (en) 2006-12-27
US10172877B2 (en) 2019-01-08
NZ593986A (en) 2013-07-26
SG150570A1 (en) 2009-03-30
CA2558676C (en) 2019-04-16
US8974774B2 (en) 2015-03-10
NO20064414L (no) 2006-12-04
JP2007527431A (ja) 2007-09-27
AU2005251676A1 (en) 2005-12-22
CR20110355A (es) 2011-09-20
US20210069224A1 (en) 2021-03-11
IL177815A0 (en) 2006-12-31
US20150320781A1 (en) 2015-11-12
EP1734984A4 (en) 2009-07-29
JP2015108006A (ja) 2015-06-11
AU2005251676B2 (en) 2011-09-29
KR101284710B1 (ko) 2013-07-23
CA2558676A1 (en) 2005-12-22
MXPA06009897A (es) 2008-02-07
IL177815A (en) 2017-07-31
KR20070024502A (ko) 2007-03-02
WO2005120546A2 (en) 2005-12-22
CA3031270A1 (en) 2005-12-22
US20200101097A1 (en) 2020-04-02
WO2005120546A3 (en) 2007-07-19
US20080038203A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
BRPI0508440A (pt) composições e métodos para diagnóstico tópico e transporte terapêutico
BRPI0508421A (pt) sistemas de transporte biológico de múltiplos componentes
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BRPI0714712B8 (pt) dispositivo para administração de fármaco
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
CY1118153T1 (el) Αγωγη μικροβιακων μολυνσεων
HK1218300A1 (zh) 基於天然抗體的靶向結構體及其應用
PE20151420A1 (es) Una composicion para tratar diabetes o diabesidad que comprende un analogo de oxintomodulina
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
MY166050A (en) Antibody formulation
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
BR112014010383A2 (pt) proteína de ligação a antígeno e uso do mesmo como produto direcionado a alvo para o tratamento de câncer
PE20171512A1 (es) Anticuerpos anti-fap
EA201100072A1 (ru) Новые композиции и способы
EA201100071A1 (ru) Новые композиции и способы
BR112014024358A2 (pt) uso de iduronate-2-sulfatase por via subcutânea e kit
EA201491369A1 (ru) Способ лечения сахарного диабета при помощи негликозилированного аполипопротеина a-iv
UY33258A (es) Proteinas de union a antigeno
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.